KEROS THERAPEUTICS IN

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

12 дек 2022 09:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at Upcoming Healthcare Conferences

22 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

07 ноя 2022 15:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

03 ноя 2022 08:00:03 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

03 ноя 2022 06:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

12 сен 2022 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

04 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

13 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

10 июн 2022 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

18 май 2022 05:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

17 май 2022 15:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

12 май 2022 15:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports First Quarter 2022 Financial Results

05 май 2022 07:00:03 Источник Nasdaq GlobeNewswire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

09 мар 2022 15:01:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 фев 2022 07:00:00 Источник Nasdaq GlobeNewswire

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

31 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

13 дек 2021 15:05:00 Источник Nasdaq GlobeNewswire